Scientists aren’t sure what’s behind the upward trend. That’s why Johnson & Johnson Innovation put out the call to address this troubling health disparity.
Harnessing the human genome is the future of healthcare—and Johnson & Johnson is helping lead the way
The company’s partnership with the largest human genome sequencing project in the world will increase scientists’ understanding of genetic diseases and help create new interventions. Here, a look at the breakthroughs that have guided the understanding of the power of DNA.
More from Johnson & Johnson
A condition called fetal and neonatal alloimmune thrombocytopenia (FNAIT) can be deadly in newborns. That’s why Johnson & Johnson is passionate about developing a treatment for the disorder.
September 20, 2023
September 20, 2023
The chronic skin condition causes itchy and scaly patches, but it’s much more than simply a cosmetic concern. For World Psoriasis Day, take this quiz to test your psoriasis IQ—and learn why Johnson & Johnson is working on new and more effective treatments for this common autoimmune disease.
Check out this infographic breakdown of the company’s third-quarter 2023 performance, with key highlights from its Innovative Medicine and MedTech businesses.
With a unique disposable camera the size of a pinkie finger, Eric Buehlmann and his team pioneered a better—and easier—way for doctors to perform back procedures.
Johnson & Johnson’s Investigational TAR-200 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer
Breakthrough Therapy Designation for Novel Targeted Releasing System Based on Results from Ongoing Phase 2b SunRISe-1 Study
Innovative investigational device designed for Left Atrial Appendage Elimination (LAAX) to reduce the risk of stroke in patients with non-valvular atrial fibrillation Strengthens position in high-growth MedTech segments
Johnson & Johnson highlights its preeminent leadership in hematology through differentiated blood cancer portfolio and pipeline with new clinical and real-world data at ASH
Data highlights strength of multi-target, multi-platform multiple myeloma portfolio and continued innovation in B-cell malignancies to transform patient outcomes